Boston Scientific Corporation (BSX)
Boston Scientific Sustains EP Momentum in Q3: Is More Upside Ahead?
BSX's Q3 EP sales soar 63% on FARAPULSE momentum, FDA label expansion and rising global adoption.
Bet on 5 Top-Ranked Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include The Chef's Warehouse, Life Time Group Holdings, The Honest Company, CorMedix and Boston Scientific.
Boston Scientific Q3: Operational Improvements Warrant An Upgrade To A Buy
Boston Scientific delivered strong Q3 results, with 20% revenue growth and beats on both top and bottom lines, prompting a rating upgrade to Buy. BSX's cardiovascular and MedSurg segments, driven by innovations like WATCHMAN and Farapulse, are fueling impressive growth and margin expansion. Management raised 2025 guidance, highlighting robust product demand, successful M&A strategy, and promising pipeline, especially in chronic pain and stroke prevention.
Here's Why Boston Scientific (BSX) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Boston Scientific (BSX) Crossed Above the 200-Day Moving Average: What That Means for Investors
After reaching an important support level, Boston Scientific (BSX) could be a good stock pick from a technical perspective. BSX surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.
Boston Scientific (BSX) Recently Broke Out Above the 50-Day Moving Average
From a technical perspective, Boston Scientific (BSX) is looking like an interesting pick, as it just reached a key level of support. BSX recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Boston Scientific Corporation (BSX) Q3 2025 Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX ) Q3 2025 Earnings Call October 22, 2025 8:00 AM EDT Company Participants Lauren Tengler - Director of Investor Relations Michael Mahoney - Chairman, President & CEO Jonathan Monson - Executive VP & CFO Ken Stein - Senior VP & Global Chief Medical Officer Conference Call Participants Robert Marcus - JPMorgan Chase & Co, Research Division Joanne Wuensch - Citigroup Inc., Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Michael Polark - Wolfe Research, LLC Travis Steed - BofA Securities, Research Division Patrick Wood - Morgan Stanley, Research Division Danielle Antalffy - UBS Investment Bank, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Christopher Pasquale - Nephron Research LLC Pito Chickering - Deutsche Bank AG, Research Division Presentation Operator Good morning, and welcome to the Boston Scientific Third Quarter 2025 Earnings Call. [Operator Instructions] Please note this event is being recorded.
Boston Scientific (BSX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Boston Scientific Beats on Q3 Earnings, Raises 2025 View, Stock Up
BSX posts strong Q3 with 19% EPS growth, lifts 2025 sales and EPS outlook as shares edge higher.
Boston Scientific (BSX) Q3 Earnings and Revenues Top Estimates
Boston Scientific (BSX) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.63 per share a year ago.
Beware The Death Cross: 3 Stocks Triggering This Spooky Signal
There are two types of Halloween people: those who like jump scares and those who don't. But even if you're a fan of haunted hayrides and movies like The Conjuring, you probably don't want to ever get a jump scare from your portfolio, which is why so many investors use diversified index funds with the bulk of their wealth.
